Advertisement

Spread through air spaces (STAS) is a predictor of poor outcome in atypical carcinoids of the lung

  • Serdar Altinay
  • Jasna Metovic
  • Federica Massa
  • Gaia Gatti
  • Paola Cassoni
  • Giorgio Vittorio Scagliotti
  • Marco VolanteEmail author
  • Mauro Papotti
Original Article
  • 2 Downloads

Abstract

Spread through air spaces (STAS) have been recently recognized as a prognostic factor for adenocarcinoma and squamous cell carcinoma of the lung. Pulmonary neuroendocrine neoplasms (NENs) include tumors with different morphology and a heterogeneous clinical behavior. Among atypical carcinoids (ACs), new prognostic factors able to refine prognosis are needed. In the present study, a retrospective series of 91 surgically resected ACs was investigated, in parallel with 191 control cases of typical carcinoids (TCs) and of high-grade small- and large-cell neuroendocrine carcinomas, to assess the presence and potential prognostic role of STAS. STAS was defined by the presence of neoplastic nests or single cells in air spaces beyond the tumor edge. Clinicopathological parameters and survival were correlated by univariate and multivariate analyses. STAS was identified in 48% of ACs (44/91) compared to 20.5% of TCs and 71–88% of high-grade large- and small-cell carcinomas in the control group. In the carcinoid group, presence of STAS was significantly correlated with unfavorable parameters, such as high tumor stage, positive nodal status, high Ki-67 index, presence of angioinvasion, and with adverse disease outcome, shorter overall survival, and time to progression. In conclusion, the presence of STAS is an additional relevant adverse prognostic factor in pulmonary AC that currently has the most unpredictable outcome and the most controversial treatment strategy.

Keywords

Lung Atypical carcinoid Neuroendocrine neoplasm Spread through air spaces (STAS) Prognosis 

Notes

Contributions

Study conception and design: MP. Data collection: SA, JM, FM, GG, PC, GVS, MV, MP. Analysis and interpretation of data: MP, MV, SA, JM, MV. Drafting of manuscript: MP, MV, SA, JM. Critical revision: SA, JM, FM, GG, PC, GVS, MV, MP. All the authors gave final approval for publication. The author MV takes full responsibility for the work as a whole, including the study design, access to data, and the decision to submit and publish the manuscript.

Funding

This study was partially supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC, Milan), grant #IG19238 to MV. JM is a PhD fellow at the University of Turin.

Compliance with ethical standards

The study was approved by the local ethical committee (Department of Oncology at San Luigi Hospital, number 17975/2015).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

428_2019_2596_MOESM1_ESM.pdf (137 kb)
Supplementary Fig 1 Histopathologic pitfalls mimicking STAS. A1/A2: mildly atypical alveolar macrophages resemble clusters of neoplastic cells. B1/B2: Chromogranin nicely highlights strongly reactive cells within STAS, but also shows some weak positivity in alveolar macrophages, as a result of passive absorption. (A1/A2: H&E staining; B1/B2: Chromogranin A immunohistochemistry; original magnification A1, B1: 100x; A2,B2: 200x) (PDF 136 kb)
428_2019_2596_MOESM2_ESM.pdf (112 kb)
Supplementary Fig 2 Kaplan Meier curves showing a significant increased risk of death in the group with 4–5 score value (p < 0.001) (PDF 112 kb)
428_2019_2596_MOESM3_ESM.pdf (365 kb)
Supplementary Fig 3 Kaplan Meier curves of overall survival analysis performed in the TC group, only. Both single cells invasion (p = 0.016) and STAS (p = 0.045) are significantly associated with shorter survival (PDF 365 kb)

References

  1. 1.
    Brierley JD, Gospodarowicz MK, Wittekin C (2017) TNM classification of malignant tumours, 8th edn. Wiley Blackwell, Oxford, pp 112–117Google Scholar
  2. 2.
    Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW, Adusumilli PS, Travis WD (2014) Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 9:1126–1139.  https://doi.org/10.1097/JTO.0000000000000253 CrossRefGoogle Scholar
  3. 3.
    Kadota K, Nitadori J, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD (2015) Tumor spread through air spaces is an important pattern of invasion and impacts the frequency and location of recurrences after limited resection for small stage I lung adenocarcinomas. J Thorac Oncol 10:806–814.  https://doi.org/10.1097/JTO.0000000000000486 CrossRefGoogle Scholar
  4. 4.
    Lu S, Tan KS, Kadota K, Eguchi T, Bains S, Rekhtman N, Adusumilli PS, Travis WD (2017) Spread through air spaces (STAS) is an independent predictor of recurrence and lung cancer-specific death in squamous cell carcinoma. J Thorac Oncol 12:223–234.  https://doi.org/10.1016/j.jtho.2016.09.129 CrossRefGoogle Scholar
  5. 5.
    Toyokawa G, Yamada Y, Tagawa T et al (2018) High frequency of spread through air spaces in resected small cell lung cancer. Anticancer Res 38:1821–1825.  https://doi.org/10.21873/anticanres.12421 CrossRefGoogle Scholar
  6. 6.
    Masai K, Sakurai H, Sukeda A, Suzuki S, Asakura K, Nakagawa K, Asamura H, Watanabe SI, Motoi N, Hiraoka N (2017) Prognostic impact of margin distance and tumor spread through air spaces in limited resection for primary lung cancer. J Thorac Oncol 12:1788–1797.  https://doi.org/10.1016/j.jtho.2017.08.015 CrossRefGoogle Scholar
  7. 7.
    Tsuta K, Raso MG, Kalhor N, Liu DD, Wistuba II, Moran CA (2011) Histologic features of low- and intermediate-grade neuroendocrine carcinoma (typical and atypical carcinoid tumors) of the lung. Lung Cancer 71:34–41.  https://doi.org/10.1016/j.lungcan.2010.04.007 CrossRefGoogle Scholar
  8. 8.
    Beasley MB, Brambilla E, Chirieac LR et al (2015) Carcinoid tumour. In: Travis WD, Brambilla E, Burke AP et al (eds) WHO classification of tumours of the lung, pleura, thymus and heart, 4th edn. IARC Press, Lyon, pp 73–77Google Scholar
  9. 9.
    Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E, Flieder DB, Geisinger K, Hirsch FR, Ishikawa Y, Kerr KM, Noguchi M, Pelosi G, Powell CA, Tsao MS, Wistuba I (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260.  https://doi.org/10.1097/JTO.0000000000000630 CrossRefGoogle Scholar
  10. 10.
    Modlin IM, Sandor A (1997) An analysis of 8305 cases of carcinoid tumors. Cancer 79:813–829CrossRefGoogle Scholar
  11. 11.
    Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119:1647–1651.  https://doi.org/10.1378/chest.119.6.1647 CrossRefGoogle Scholar
  12. 12.
    Skuladottir H, Hirsch FR, Hansen HH, Olsen JH (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37:127–135.  https://doi.org/10.1016/S0169-5002(02)00080-6 CrossRefGoogle Scholar
  13. 13.
    Rindi G, Klersy C, Inzani F, Fellegara G, Ampollini L, Ardizzoni A, Campanini N, Carbognani P, de Pas TM, Galetta D, Granone PL, Righi L, Rusca M, Spaggiari L, Tiseo M, Viale G, Volante M, Papotti M, Pelosi G (2013) Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr Relat Cancer 21:1–16.  https://doi.org/10.1530/ERC-13-0246 CrossRefGoogle Scholar
  14. 14.
    Pelosi G, Rindi G, Travis WD, Papotti M (2014) Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol 9:273–284.  https://doi.org/10.1097/JTO.0000000000000092 CrossRefGoogle Scholar
  15. 15.
    Marchiò C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M (2017) Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch 471:713–720.  https://doi.org/10.1007/s00428-017-2177-0 CrossRefGoogle Scholar
  16. 16.
    Eguchi T, Kameda K, Lu S, Bott MJ, Tan KS, Montecalvo J, Chang JC, Rekhtman N, Jones DR, Travis WD, Adusumilli PS (2019) Lobectomy is associated with better outcomes than sublobar resection in spread through air spaces (STAS)-positive T1 lung adenocarcinoma: a propensity score-matched analysis. J Thorac Oncol 14:87–98.  https://doi.org/10.1016/j.jtho.2018.09.005 CrossRefGoogle Scholar
  17. 17.
    Uruga H, Fujii T, Fujimori S, Kohno T, Kishi K (2017) Semiquantitative assessment of tumor spread through air spaces (STAS) in early-stage lung adenocarcinomas. J Thorac Oncol 12:1046–1051.  https://doi.org/10.1016/j.jtho.2017.03.019 CrossRefGoogle Scholar
  18. 18.
    Lapere C, Cortot AB, Gregoire V et al (2017) Preferential localization of MET expression at the invasion front and in spreading cells through air spaces in non–small cell lung carcinomas. Am J Surg Pathol 41:414–422.  https://doi.org/10.1097/PAS.0000000000000810 CrossRefGoogle Scholar
  19. 19.
    Richards-Taylor S, Ewings SM, Jaynes E, Tilley C, Ellis SG, Armstrong T, Pearce N, Cave J (2016) The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. J Clin Pathol 69:612–618.  https://doi.org/10.1136/jclinpath-2015-203340 CrossRefGoogle Scholar
  20. 20.
    Hendifar AE, Marchevsky AM, Tuli R (2017) Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well-differentiated disease. J Thorac Oncol 12:425–436.  https://doi.org/10.1016/j.jtho.2016.11.2222 CrossRefGoogle Scholar
  21. 21.
    Caplin ME, Baudin E, Ferolla P, Filosso P, Garcia-Yuste M, Lim E, Oberg K, Pelosi G, Perren A, Rossi RE, Travis WD (2015) Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Ann Oncol 26:1604–1620.  https://doi.org/10.1093/annonc/mdv041 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Serdar Altinay
    • 1
  • Jasna Metovic
    • 2
  • Federica Massa
    • 2
  • Gaia Gatti
    • 2
  • Paola Cassoni
    • 3
  • Giorgio Vittorio Scagliotti
    • 2
  • Marco Volante
    • 2
    Email author
  • Mauro Papotti
    • 2
  1. 1.Division of PathologyUniversity of Health Sciences, Dr. Sadi Konuk Training and Research HospitalIstanbulTurkey
  2. 2.Pathology Division of the Department of OncologyUniversity of TurinTorinoItaly
  3. 3.Pathology Division of the Department of Medical SciencesUniversity of TurinTurinItaly

Personalised recommendations